MiR-217 Promotes Tumor Proliferation in Breast Cancer via Targeting DACH1

Journal of Cancer

Volumn 6, Issue 2, 2015, Pages 184-191

  Zhang, Qiang ^a   Yuan, Yonghui ^a   Cui, Jianchun ^b   Xiao, Tingting ^c   Jiang, Daqing ^a  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^b Department of Surgery   (China)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Breast cancer; Cell cycle; DACH1; MiR 217; Proliferation

Indexed keywords

CYCLIN D1; DACH1 PROTEIN; MICRORNA; MICRORNA 217; PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ADVANCED BREAST CANCER; ARTICLE; BINDING SITE; CANCER STAGING; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUCIFERASE ASSAY; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T-47D CELL LINE; TRANSIENT TRANSFECTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; WILD TYPE; XENOGRAFT;

EID: 84930202655     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/JCA.10822     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
3. Poortmans P, Marsiglia H, De Las Heras M, Algara M. Clinical and technological transition in breast cancer. Rep Pract Oncol Radiother. 2013; 18: 345-52.
4. Rivenbark AG, O'Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013; 183: 1113-24.
5. Chen R, Amoui M, Zhang Z, Mardon G. Dachshund and eyes absent proteins form a complex and function synergistically to induce ectopic eye development in Drosophila. Cell. 1997; 91: 893-903.
6. Shen W, Mardon G. Ectopic eye development in Drosophila induced by directed dachshund expression. Development. 1997; 124: 45-52.
7. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res. 2006; 66: 8404-12.
8. Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, et al. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol. 2006; 26: 7116-29.
9. Dalgin GS, Drever M, Williams T, King T, DeLisi C, Liou LS. Identification of novel epigenetic markers for clear cell renal cell carcinoma. J Urol. 2008; 180: 1126-30.
10. Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci. 2008; 99: 2193-9.
11. Wu K, Liu M, Li A, Donninger H, Rao M, Jiao X, et al. Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. Mol Biol Cell. 2007; 18: 755-67.
12. Wu K, Katiyar S, Li A, Liu M, Ju X, Popov VM, et al. Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proc Natl Acad Sci U S A. 2008; 105: 6924-9.
13. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, et al. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics. 2013; 8: 1373-83.
14. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5: 522-31.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
16. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006; 11: 441-50.
17. Nan F, Lu Q, Zhou J, Cheng L, Popov VM, Wei S, et al. Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biol Ther. 2009; 8: 1534-9.
18. Silveri L, Tilly G, Vilotte JL, Le Provost F. MicroRNA involvement in mammary gland development and breast cancer. Reproduction, nutrition, development. 2006; 46: 549-56.
19. Khoshnaw SM, Green AR, Powe DG, Ellis IO. MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol. 2009; 62: 422-8.
20. Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG. microRNA, cell cycle, and human breast cancer. Am J Pathol. 2010; 176: 1058-64.
21. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302: 1-12.
22. de Yebenes VG, Bartolome-Izquierdo N, Nogales-Cadenas R, Perez-Duran P, Mur SM, Martinez N, et al. miR-217 is an oncogene that enhances the germinal center reaction. Blood. 2014; 124: 229-39.
23. Su J, Wang Q, Liu Y, Zhong M. miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. Mol Cell Biochem. 2014; 392: 289-96.
24. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010; 31: 1726-33.
25. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009; 220: 292-6.
26. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9: 153-66.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
28. Velasco-Velazquez MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG. Examining the role of cyclin D1 in breast cancer. Future Oncol. 2011; 7: 753-65.
29. Zhang Q, Sakamoto K, Wagner KU. D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells. Mol Cell Endocrinol. 2014; 382: 583-92.